Russia’s Binnopharm will enjoy exclusive rights to develop, register, manufacture, and market Mabwell’s biosimilar Humira (adalimumab) and Prolia/Xgeva (denosumab) candidates under the terms of a licensing agreement struck between the firms covering Russia and the Eurasian Economic Union.
The Chinese biotech noted that the alliance’s target was for its Russian partner to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?